AstraZeneca agrees to a deal potentially worth $1.5 billion to acquire global rights for the lung cancer drug Sunvozertinib from China's Dizal Pharmaceutical. The deal includes a $600 million upfront payment. The drug, also known as Zegfrovy, is an oral treatment for non-small cell lung cancer and is already approved in the U.S. and China, adding a commercial-ready asset to AstraZeneca's oncology portfolio.
AstraZeneca acquisition deal
- ▪AstraZeneca will pay China’s Dizal Jiangsu Pharmaceutical Co. $600 million upfront for global rights to a lung cancer drug
- ▪Dizal Pharmaceutical is eligible to receive up to $900 million in additional payments based on clinical and sales-related milestones
- ▪The total potential value of the deal between AstraZeneca and Dizal Pharmaceutical is $1.5 billion
Sunvozertinib drug profile
- ▪The drug was approved in the U.S. in July 2025 but has not yet been launched in the country
- ▪Sunvozertinib is approved in the U.S. and China for adults with locally advanced or metastatic non-small cell lung cancer
- ▪The drug, Sunvozertinib (also known as Zegfrovy), is an oral treatment for a subset of non-small cell lung cancer
- ▪Non-small cell lung cancer constitutes about 77% of all lung cancers, according to the American Cancer Society
Clinical trial results
- ▪In the trial, patients on Sunvozertinib had a median progression-free survival of 10.3 months, versus 7.5 months for those on chemotherapy
- ▪A late-stage multinational clinical trial of Sunvozertinib involved 324 patients
Global commercialization rights
- ▪As part of the deal, AstraZeneca will gain global development and commercialization rights to Sunvozertinib
- ▪The acquisition adds a commercial-ready treatment to AstraZeneca's franchise and is part of a wave of deals from China
Story comments
Loading comments…